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1 GENERAL PART 
1.1 Introduction 
1.1.1 Cannabinoid (CB) Receptor Agonists 
1.1.1.1 Δ9-Tetrahydrocannabinol (THC) 
The cannabis plant (Cannabis sativa) has been discovered millennia ago and ancient 
cultures have already benefited from its therapeutic properties [1]. Until today, great 
importance is attributed to Cannabis sativa as medicinal plant. Due to its analgesic, 
antiemetic, and appetite stimulating effects, it is often used in the treatment of e.g. 
multiple sclerosis, cancer, or neurodegenerative diseases such as Huntington 
disease [2,3]. Besides its medicinal usage, psychoactive effects of cannabis, such as 
euphoria and alteration of conscious perception have already been utilized by our 
ancestors [1,4]. Nowadays, cannabis is one of the commonly consumed drugs of 
abuse worldwide [5] and has become an issue in forensic toxicology, especially in 
driving under the influence of drugs (DUID) cases [6-8]. In addition, this drug is 
associated with a high tolerance, dependence, and withdrawal potential [9-11]. 
The cannabis plant contains more than 60 cannabinoids, with THC (Fig. 1) being the 
principal psychoactive ingredient [12]. It has been isolated in the 1960s [13], resulting 
in an increasing interest of researchers. This research also included the elucidation of 
THC metabolism [14] and the main metabolites were found to be the psychoactive 
11-hydroxy-THC (11-HO-THC; Fig. 1) and the pharmacologically inactive 11-nor-9-
carboxy-THC (THC-COOH; Fig. 1). 
 
 
 
Fig. 1 Structure of THC and its main metabolites. 
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Only few years ago, two G-protein-coupled receptors, CB1 and CB2 [15-17], were 
identified to be responsible for the pharmacological actions of cannabinoids e.g. by 
inhibition of the adenylyl cyclase activity with a consecutive decrease in cyclic 
adenosine monophosphate (cAMP) accumulation, resulting in the inhibition of cAMP-
dependent kinases [18,19]. The central nervous system (CNS) is thought to be the 
predominant localization of CB1 receptors, with highest densities in the basal ganglia, 
substantia nigra, globus pallidus, cerebellum, and hippocampus, giving the ultimate 
explanation for the psychoactive effects [19]. On the contrary, CB2 receptors are 
mainly detected in peripheral cells of the immune system, but also (with very low 
densities) in microglial cells of the CNS [19]. THC was identified to bind with similar 
affinity to both receptors and act as a partial agonist [20-22]. The identification and 
cloning of the CB receptors led to the discovery of the endocannabinoid system 
[23,24] and to a boom in the cannabinoid researching field. Many so-called 
nonclassical cannabinoids, structurally distinct from THC, were synthesized, 
promising to be alternative compounds with higher therapeutic potential and higher 
affinity to the CB1 receptor, but with less adverse effects [25]. 
 
1.1.1.2 Synthetic cannabinoids (SCs) 
A few series of these non-classic cannabinoids e.g. napthoylindole derivatives were 
synthesized by J.W. Huffman for structure-activity relationship studies [26-28]. 
According to the initials of their inventor, these compounds were called JWH 
compounds. Two examples of napthoylindole derivatives are naphthalen-1-yl-(1-
pentylindol-3-yl)methanone (JWH-018) and 4-ethylnaphthalen-1-yl-(1-pentylindol-3-
yl)methanone (JWH-210; structures depicted in Fig. 2).  
N
O R
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Fig. 2 Examples of naphthoylindole derivatives. 
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In comparison to THC, SCs often displayed higher affinity to CB1 receptors [26-28]. 
Unlike its natural pendant, these chemically derived CBs often appeared to be full 
agonists on CB receptors, characterized by considerably high efficiencies [29-31]. 
Accordingly, rising consequences, such as undesirable psychoactive effects, led to a 
diminished experimental ambition in pharmacological research [25]. 
However, taking advantage of these properties, SCs have become attractive legal 
alternatives to cannabis as recreational drugs a few years ago. In 2008, JWH-018 
was identified as one of the first active ingredients in a so-called herbal incense 
product called ‘Spice’ [30,31]. Before this identification, it was the common belief that 
the contained herbs such as Leonotis leonuru (‘Lion’s ear/tail’, ‘Wild dagga’ [30]) 
were responsible for the pharmacological effects that were observed after 
consumption of these herbal products. Instead, it was found that the SCs were 
supplementary added (mainly sprayed) to the herbal contents [30,32].  
Until then, various SCs have increasingly been synthesized in clandestine 
laboratories and distributed via the internet in herbal incenses [30,33]. Not only 
naphthoylindoles, but also other groups of SCs, such as the benzoylindole 2-(4-
methoxyphenyl)-1-(1-pentylindol-3-yl)methanone (RCS-4; Fig. 3), were uncovered in 
herbal incenses [34]. 
 
N
O O
 
Fig. 3 Structure of the benzoylindole RCS-4. 
 
However, the actual type and concentration of the contained SCs were notably 
fluctuating, even from one batch to another of the same product. After having 
successfully banned certain types of derivatives, the next generation of SCs followed 
by distributing them under the same brand in order to circumvent law [35]. Figure 4 
shows the number of distribution of the newly identified new psychoactive substances 
(NPS), notified by the European (EU) Early Warning System (EWS). It is apparent 
that the number of SCs significantly increased over the last six years. 
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Fig. 4 Number and categories of newly identified NPS notified by the EU EWS from 
2005-2014 (data and graph of the European Monitoring Centre [36]). 
 
Officially, the herbal incenses were marked with the advice ‘not for human 
consumption’. Obviously, they were not used to condition the air of a room, but rather 
misused (mainly smoked) as recreational drugs. The prevalence of SC use differs 
between EU countries and the United States (US). In Germany, lifetime levels of the 
use of herbal mixtures among students (15 to 18 years) were 7% in 2009, 9% in 
2010, 7% in 2011 and 7% in 2012 [33]. In France, a global survey for adults (18 to 64 
years) revealed SC experimentation rates of 1.7% in 2014 [33]. Regarding the US, a 
survey about NPS use by adolescents for the years 2012-2014 resulted in 3.5% SC 
use in the past 12 months by 8th graders, 7.2% of 10th graders, and 8.3% of 12th 
graders [37]. Besides the legal status of new emerging SCs, along with their 
cannabis-related effects, consumption is additionally triggered by the facts that these 
substances are affordable, easily accessible via the internet, and not covered by 
routine toxicological analysis [38]. In fact, SC consumption became even more 
forensically relevant in terms of DUID cases, because of a potential impairment of the 
driver [39,40].  
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Withal, it has to be considered that these compounds are sold and consumed without 
safety pharmacological tests. Due to their high potency and efficacy together with the 
highly dynamic market and an uncontrolled production of the herbal incenses, users 
are always exposed to a risk of strong psychoactive and unpredictable toxic effects. 
Numerous cases of intoxications have been reported with life-threatening conditions 
accompanied e.g. by tachycardia, somnolence, anxiety, nausea, vomiting, seizures, 
hyperglycemia, hypokalemia, agitation, hallucination, and acute psychosis [41-44]. A 
case series of mono-intoxications with JWH-210 provided more knowledge of 
adverse effects and clinical manifestations of SCs [45]. Alarming symptoms such as 
seizures, agitation, and severe vomiting, all atypical symptoms for cannabis, can be 
explained by the fact that SCs are full CB1 receptor agonists [46]. In addition, even 
deaths involving SCs have been reported [43,47-50]. Similar to THC, SCs can cause 
tolerance, dependence, and withdrawal [38].  
Taking all these findings together, SCs have become a tremendous public health 
concern and are gaining an increasing importance in clinical and forensic toxicology. 
When interpreting analytical data of impaired or poisoned persons in concern of e.g. 
the time of intake or concentration at a particular time, explicit pharmacokinetic (PK) 
data are indispensable, especially when it comes to profound expert opinion in e.g. 
DUID cases. Even though systematic controlled administration studies are needed, 
the lack of pre-clinical safety studies does not allow for conducting human studies. 
Thus, comparable standards by use of animal models have to be established. One 
important step in elucidating PK data should be the assessment of serum-
concentration-time profiles in comparison to those obtained from the already well-
studied THC (see chapter 2.3).  
1.1.2 Detection Methods in Biological Matrices 
Understanding the PK of a drug requires the determination of the concentration in 
biological matrices, especially in blood/serum. Regarding the quantification of THC 
and its main metabolites HO-THC and THC-COOH, many studies using blood and 
urine as standardized biological specimens have been published. As summarized in 
different reviews, in the past, gas chromatography-mass spectrometry was the gold 
standard in detecting and quantifying cannabinoids after solid-phase extraction (SPE) 
or liquid-liquid extraction (LLE) [51-53]. In recent years, liquid-chromatography-
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tandem mass spectrometry (LC-MS/MS) has increasingly been applied [51,54,55]. As 
a result, more sensitive procedures with short runtimes and reduced sample 
preparation could be developed. For molecule ionization, electrospray (ESI) or 
atmospheric pressure chemical ionization (APCI) were used, however, APCI 
appeared to be more suitable for cannabinoid detection as compared to ESI [51]. For 
more details see Chapter 2.1. 
Regarding SCs determination in biological matrices, several reviews dealing with 
mainly LC-MS/MS based methods after e.g. SPE or LLE have been published 
recently [56-59]. Despite that, none of these methods allowed for simultaneous 
determination of THC, SCs and their metabolites needed to elucidate PK properties 
in blood. A new LC-MS/MS assay using one ionization technique should therefore be 
developed and validated according to national and international guidelines ([60,61]; 
see Chapter 2.1). 
1.1.3 Pharmacokinetics 
1.1.3.1 Metabolic Patterns 
When conducting a study on PK, the elucidation of the metabolic patterns of the drug 
under investigation should be included. In order to obtain more insight into analytical 
data interpretation in cases of suspected intoxication or in abstinence monitoring 
programs, doping analysis, and workplace drug testing, the knowledge of the 
analytical target for urinalysis, which is basically preferred in these cases, is 
necessary.  
In general, endogenous and exogenous lipophilic compounds, such as drugs, are 
metabolized (mainly by the liver) to more hydrophilic and often pharmacologically 
inactive compounds that can be excreted, mainly via urine. The metabolic reactions 
proceed in two different phases. In so-called functionalizing phase I reactions, 
compounds are modified by e.g. hydroxylation, oxidation, epoxidation, or 
dealkylation. These reactions are often catalyzed by cytochrome P450 
monooxigenases (CYP; [59,62]). Following the phase I reactions, the modified 
compounds are further conjugated e.g. with glucuronic or sulfuric acid in phase II 
reactions by conjugating enzymes, such as uridine 5'-diphospho-
glucuronosyltransferases or sulfotransferases. 
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In the matter of THC, nearly 100 metabolites have been identified. Main phase I 
reactions are hydroxylation (principally at C-11 to 11-HO-THC) and further oxidation 
to the carboxylic acid (THC-COOH). These phase I metabolites, as well as THC 
itself, are extensively glucuronidated [63]. 
Regarding SCs, recently published reviews summarized the results of in vitro and in 
vivo biotransformation studies [59], and provide a comprehensive overview of 
developments in urinalysis of SC metabolites [64]. SCs are very lipophilic compounds 
and primarily excreted into urine via their metabolites. The main metabolic phase I 
steps include aromatic and aliphatic hydroxylation, followed by further oxidation of 
aliphatic hydroxy metabolites to ketones or carboxylic acids, N-dealkylation, oxidative 
defluorination (of those SCs containing a fluorine atom), and O-demethylation (of 
those containing a methoxy group; [59,64]). The main metabolic phase II reactions 
were observed to be glucuronidation or sulfation, while the major metabolites seem to 
be extensively glucuronidated [59]. 
Two approaches are commonly used for metabolite elucidation. At first, the in vitro 
assay with liver microsomes or hepatocytes [65,64]. In comparison to data derived 
from authentic cases, this method offers the advantage of unequivocally assessing 
the metabolites of the known parent compound. One disadvantage is that the formed 
metabolites are not necessarily excreted into urine and thus, urinary metabolite 
patterns may differ. Therefore, a confirmation in authentic urine specimens is 
needed. As already mentioned above, no pre-clinical data are available as far as SCs 
are concerned, and except for self-experiments (allowed in some countries), 
controlled human studies are not possible. For this purpose, authentic human urine 
from clinical or forensic cases can be used [64]. However, this approach is limited by 
the fact that type and dosage of the consumed drug/s, as well as time and frequency 
of consumption are mainly unknown. Hence, experimental studies by using animal 
models (in vivo) under controlled conditions remain as a second common approach 
[64]. One advantage of animal models as compared to the in vitro assay is that they 
reflect systemic processes following drug intake similar to human pathways. 
Furthermore, excretion patterns covering a certain period of time can be pointed out. 
Yet, species differences regarding metabolism rate and types of formed metabolites, 
attributable to differences in enzyme patterns, remain possible [66]. The most 
common animals used for such experiments were rats [67-70]. However, pigs as 
large mammals, are not only advantageous when it comes to the quantity of 
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specimen sampling, but also convenient for scientific research on metabolism [71-
73]. This is underlined by the fact that they are closely related to humans in terms of 
CYP enzyme patterns [74], anatomical structures as well as physiological properties 
regarding e.g. cardiovascular, urogenital, nutrition, and digestive systems [75,76]. In 
the comprehensive PK study conducted in this work, it should therefore be examined 
if the pig reflects human metabolic THC and SC patterns (see Chapter 2.2).   
 
1.1.3.2 Distribution in blood and tissues 
When investigating PK properties of a substance, the route of administration should 
be deliberated. The distribution of a substance strongly depends on the route of 
administration and hence, on the bioavailability. After pulmonary administration, 
which is the primary route for THC and SCs (by smoking; [59,63]), the bioavailability 
is less than 100%, depending on different issues such as frequency, depth of puffs, 
and amount of pyrolytic destruction. Oral ingestion (sometimes chosen for THC and 
SC administration [59,63] ) also results in less than 100% bioavailability, because the 
whole amount of the substance usually does not pass bio membranes and first-pass 
metabolism can reduce the absorbed amount. Anyhow, passing bio membranes and 
reaching the circulation is a basic principal in developing pharmacological activity. In 
addition, the concentration of the parent compound can be reduced during the first 
liver passage due to biotransformation. Focussing on THC and SCs, pulmonary or 
oral administrations reflect authentic user habits. Nevertheless, using these routes of 
administration, the exact amount of substance reaching the circulation remains 
speculative. In contrast, an intravenous (i.v.) administration bears the advantage of a 
100% bioavailability. Conclusively, the whole amount of unchanged drug reaches the 
systemic circulation and thus providing an exact quantification to establish a PK 
model.  
A PK study is often associated with a so-called compartmental analysis. In detail, this 
complex mathematical model yields additional help in predicting and describing the 
concentration-time profile of a substance by means of parameters, such as area 
under the blood-concentration-time curve (AUC), elimination half-lifes (t½), volumes of 
distribution (Vd), or clearances (Cl). The AUC is defined as the integral of the 
concentration-time curve, t½ of a substance is that time, the drug concentration needs 
to halve, Vd is the apparent volume in which a drug is distributed, and Cl is the 
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volume of blood cleared of the substance per time unit. The parameters are related to 
each other, as described by different equations  [77]. In the context of compartmental 
analysis, it has to be distinguished between two models. In a one-compartmental 
model, the body acts as a single compartment, into which the substance is 
distributed. On the other hand, describing the PK of a substance by a multi-
compartment model, does not only consider the distribution into a central 
compartment (blood and rapidly equilibrating tissues), but also the distribution into 
one or few peripheral compartments (slowly equilibrating tissues), as well as a 
redistribution between them [77]. A typical concentration-time profile of a substance 
after i.v. administration described by a three-compartment model is schematically 
presented in Fig. 5. It consists of a distribution, elimination and tissue release phase 
(α, β, γ phase) 
 
Fig. 5 Concentration-time profile of a substance described by a three-compartment 
model. 
 
As far as THC is concerned, the PK has extensively been described in animals and 
humans using different routes of administration [63,78]. Seeing that, THC 
concentrations rapidly declined after i.v. administration and at the end of smoking, 
respectively. As opposed to the inhalation of THC, i.v. administration resulted in 
higher concentrations due to issues already discussed above. The significant 
decrease of THC concentrations was typically attributable to a (mainly hepatic) 
metabolism and a rapid distribution into highly perfused tissues (e.g. brain, lung, 
liver). After oral administration, concentrations were significantly lower because of 
degradation of THC in the stomach and an extensive first-pass metabolism [63,78]. 
THC has been identified to fit multi-compartment models [63]. For detailed 
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information see Chapter 2.4. By reason of its high lipophilic nature, THC was stored 
in adipose tissue and could be redistributed into the bloodstream, resulting in long 
terminal t½ [63,78]. Especially after chronic consumption, longer windows of detection 
owing an accumulation and retarded release from adipose tissue, have to be 
expected. The storage in adipose tissue displays an important issue that has to be 
considered when interpreting analytical data of forensic toxicological cases. In this 
context, the usually unknown consumption habits of chronic users have to be 
additionally taken into consideration. 
This phenomenon has also been discussed for SCs, because they are also very 
lipophilic compounds [79]. Though, as already mentioned, detailed knowledge on SC 
PK properties is lacking. In a review by Castaneto et al. [59], recent investigations on 
blood and tissue distribution in humans and animals have been summarized. Unlike 
the few systematic animal studies that have been conducted, the majority of the 
human studies were self-experiments with only one or two participants. Apart from 
that, SC tissue distribution has been described in several fatal cases [50,80-83]. 
Even so, as already mentioned, data from authentic cases always bear the 
disadvantage of certain imponderables. SCs seem to behave similar to THC after 
administration, resulting e.g. in a rapid decrease of concentrations and accumulation 
in brain and adipose tissue. For more details see Chapter 2.4. Nevertheless, data are 
limited and should be completed by systematic controlled animal studies, as human 
studies are not approved for ethical reasons. As an alternate to expensive mammals, 
such as dogs and monkeys, pigs are increasingly used in preclinical toxicological 
testing of pharmaceuticals [76] and they are a common model in pharmacological 
studies, especially to assess PK properties of substances [73,84,85]. In addition, the 
pig was found to be suitable to elucidate the THC PK [71,86]. SC PK properties 
including blood and tissue distribution in comparison to THC should therefore be 
assessed using the pig (see Chapter 2.4). 
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1.2 Aims of the dissertation  
 
Synthetic cannabinoids are becoming an increasing public health concern. 
Pharmacokinetic data are indispensable for a reliable interpretation of analytical data 
from clinical and forensic toxicological cases to provide substantial expert opinion in 
e.g. poisoning or Driving-Under-the-Influence-of-Drugs cases. However, pre-clinical 
pharmacologically studies are not available and controlled human studies are not 
allowed. Thus, systematic controlled animal models have to be established. 
Therefore, the aims of this dissertation are given below: 
 
• Development of an analytical LC-MS/MS method for the simultaneous 
determination of JWH-210, RCS-4, THC, and their main metabolites in pig and 
human serum, whole blood, and urine 
• Elucidation of metabolic patterns of the studied drugs in pig urine using LC-
high resolution (HR)-MS/MS and comparison with published human data  
• Distribution of the studied SCs and THC including a representative choice of 
specimens, such as relevant organs, tissues, and important body fluids e.g. 
bile, in addition to blood and urine, after i.v. administration to pigs  
• Determination of concentration-time profiles of the investigated SCs after i.v. 
administration to pigs in comparison to that of THC 
• Modeling of the concentration-time profiles and assessment whether this 
model can predict published THC data in humans 
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2  PUBLICATION OF THE RESULTS  
The results of the dissertation studies were published in the following papers: 
 
2.1 Simultaneous LC-MS/MS determination of JWH-210, RCS-4, delta9-
tetrahydrocannabinol, and their main metabolites in pig and human 
serum, whole blood, and urine for comparing pharmacokinetic data [87] 
(DOI: 10.1007/s00216-015-8605-6); 
http://link.springer.com/article/10.1007%2Fs00216-015-8605-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
2.2 Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated 
using LC-HR-MS/MS – Do they reflect patterns in humans? [88]  
(DOI: 10.1002/dta.1995; hyperlink not yet provided) 
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2.3 Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance 
for clinical and forensic toxicology [89] 
(DOI: 10.1016/j.toxlet.2016.04.021); 
http://www.sciencedirect.com/science/article/pii/S0378427416300790 
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2.4 Distribution of JWH-210, RCS-4, and ∆9-Tetrahydrocannabinol after 
intravenous administration to pigs [90] 
(accepted by mail of 04/26/2016; DOI and hyperlink not yet provided) 
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3 DISCUSSION AND CONCLUSIONS  
 
The presented studies provide data on the PK of the two model SCs JWH-210 and 
RCS-4, as well as of THC obtained after controlled i.v. administration to pigs. Their 
major phase I and phase II metabolites and their metabolic patterns were elucidated 
in urine specimens. Regarding JWH-210, the major metabolic pathways were 
hydroxylation at the ethyl side chain or N-pentyl side chain and combinations of them 
followed by glucuronidation. The analysis of the N-hydroxypentyl glucuronide 
(detectable for 3-4 h) might be helpful to prove JWH-210 consumption. Concerning 
RCS-4, the main metabolic steps were hydroxylation at the methoxyphenyl moiety or 
N-pentyl side chain followed by glucuronidation as well as O-demethylation followed 
by glucuronidation or sulfation. In urinalysis, targets for RCS-4 intake might be the 
glucuronides of the N-hydroxypentyl, hydroxy-methoxyphenyl (detectable for at least 
6 h), and the O-demethyl-hydroxy metabolites (detectable for 4 h). Regarding THC, 
THC glucuronidation, 11-hydroxylation, followed by carboxylation and glucuronidation 
was observed. SC parent compounds could not be detected in urine in contrast to 
THC. Apart from some minor differences, the results of this pig study were consistent 
with the results obtained from human hepatocytes and/or human cases. This 
suggests that pigs are a suitable model for the elucidation of (human) SC 
metabolism.  
In a next step, an LC-MS/MS method was developed and fully validated to determine 
simultaneously THC and the SCs in blood and urine and to assess the serum-
concentration-time profiles of these substances. Subsequently, a population PK 
three-compartment model was successfully developed describing the serum-
concentration-time profiles. Based on that pig PK model, human THC exposure was 
successfully predicted, proposing that pigs together with PK modeling technique may 
be a useful tool for prediction of human PK of SCs. Since no preclinical safety studies 
have been performed before marketing and thus no PK data are available, this may 
help in interpretation of authentic clinical and toxicological cases. Following this pilot 
study, an administration by smoking, reflecting better the habits of users, the 
application of an extended sampling protocol, and the usage of a higher number of 
animals might further improve the predictive performance of the model.  
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In a last step, a representative collection of specimens, including relevant organs, 
tissues, and important body fluids, such as bile, was conducted to investigate major 
distribution patterns of the examined drugs. Regarding the parent compounds, the 
distribution patterns were similar with two exceptions. RCS-4 and THC persisted in 
lung tissues, while JWH-210 was stored in the kidneys. Insofar, toxicological analysis 
of these organs is recommended in forensic postmortem toxicology. Storage of the 
three drugs in adipose and muscle tissue could be observed, implying these matrices 
to be appropriate for SC and THC postmortem detection, particularly if other 
specimens are no more available. Brain tissue could also serve as alternative 
specimen. As far as the metabolites are concerned, concentrations were basically 
highest in tissues involved in metabolism and/or elimination. N-Hydroxypentyl RCS-4 
(HO-RCS-4) was the most prevalent metabolite found in almost every tissue or body 
fluid. Kidney tissue was suitable for detection of THC-COOH, HO-RCS-4, and RCS-4 
pentanoic acid. Though, bile fluid was the most suitable specimen for SC and THC 
metabolite detection. 
In conclusion, the presented results indicate that this pig model served as valid model 
for elucidating PK properties of SCs. Moreover, further systematic PK studies of 
other, new emerging SCs should be performed applying this particular model. 
Furthermore, important knowledge on the PK of this hazardous drugs class might be 
offered using pigs and the PK modeling approach. This is expected to improve the 
interpretation of analytical data obtained from misuse and poisoning cases and finally 
to provide scientifically based expert opinion in e.g. DUID cases. 
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5  ABBREVIATIONS 
11-HO-THC  
APCI 
AUC 
cAMP 
CB 
11-hydroxy-THC 
atmospheric pressure chemical ionization 
area under the concentration-time curve 
cyclic adenosine monophosphate 
cannabinoid 
Cl 
CNS 
CYP 
DUID  
ESI 
EU 
clearance 
central nervous system 
cytochrome P450 
driving under the influence of drugs 
electrospray ionization 
European 
EWS 
i.v. 
JWH-018 
JWH-210 
LC-MS/MS 
LLE 
NPS 
PK 
RCS-4 
SCs 
Early Warning System 
intravenous 
naphthalen-1-yl-(1-pentylindol-3-yl)methanone 
4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone 
liquid-chromatography tandem mass spectrometry 
liquid-liquid extraction 
new psychoactive substances 
pharmacokinetic 
2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)methanone 
synthetic cannabinoids 
SPE 
t½ 
THC 
THC-COOH 
solid-phase extraction 
elimination half-life  
Δ9-tetrahydrocannabinol 
11-nor-9-carboxy-THC 
US United States 
Vd volume of distribution  
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6 SUMMARY 
Synthetic cannabinoids (SCs) are gaining increasing importance in clinical and 
forensic toxicology. Neither preclinical safety data nor data obtained from controlled 
human studies are available. Thus, alternative models for assessment of 
pharmacokinetic (PK) data have to be established for improved interpretation of 
authentic clinical and forensic cases. In the presented studies, the PK of the two SCs 
JWH-210 and RCS-4 has been elucidated after intravenous administration to pigs. In 
addition, the PK of tetrahydrocannabinol (THC) has been assessed to examine the 
comparability of porcine and human PK. The major urinary metabolic SC pathways 
were aromatic and aliphatic hydroxylation, as well as O-demethylation (RCS-4) 
followed by glucuronidation or sulfation (RCS-4). Regarding THC, THC 
glucuronidation, hydroxylation and carboxylation followed by glucuronidation were 
the known major metabolic steps. With few exceptions, the results of this pig study 
were in good agreement with those obtained from human hepatocytes and/or human 
cases. A population PK modeling approach revealed that a three-compartment model 
described best the concentration-time profiles. In addition, the pig PK model has 
proven to be suitable for prediction of human THC exposure. The investigation of 
distribution patterns of the drugs revealed that particularly the analysis of lungs, 
kidneys, brain, adipose and muscle tissue, and bile is recommended in postmortem 
toxicology. 
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7 ZUSAMMENFASSUNG 
Synthetische Cannabinoide (SC) gewinnen zunehmende Bedeutung in der klinischen 
und forensischen Toxikologie. Weder präklinische Sicherheitsdaten, noch Daten aus 
kontrollierten Humanstudien sind verfügbar. Die Etablierung alternativer Modelle zur 
Auswertung von Pharmakokinetik (PK)-Daten ist notwendig, um eine verbesserte 
Interpretation authentischer Daten zu gewährleisten. In den vorgestellten Studien 
wurde die PK der beiden SC JWH-210 und RCS-4 nach intravenöser Gabe in 
Schweinen aufgeklärt und ebenfalls Tetrahydrocannabinol (THC) bestimmt, um die 
Vergleichbarkeit der PK in Schwein und Mensch zu überprüfen. Die 
Hauptmetabolismuswege der SC im Urin waren aromatische und aliphatische 
Hydroxylierung sowie O-Demethylierung (RCS-4), gefolgt von Glucuronidierung oder 
Sulfatierung (RCS-4). Hauptmetabolismusschritte von THC waren, wie bekannt, 
THC-Glucuronidierung, Hydroxylierung und Carboxylierung, gefolgt von 
Glucuronidierung. Mit wenigen Ausnahmen stimmen die Ergebnisse gut mit denen 
aus Studien mit humanen Hepatozyten oder aus Fallberichten überein. Ein 
populationskinetischer Modellierungsansatz ergab, dass ein Drei-Kompartiment-
Modell die Konzentrations-Zeit Profile am besten beschreibt. Außerdem scheint das 
Schweinemodell geeignet zur Vorhersage humaner THC Exposition zu sein. Die 
Ermittlung der Verteilungsmuster der Drogen zeigte, dass insbesondere die Analyse 
von Lungen, Nieren, Gehirn, Fett- und Muskelgewebe und Galle in der Postmortem-
Toxikologie empfehlenswert ist.  
 
